5. clinically stable disease, no exacerbations of asthma within 3 months prior to inclusion requiring oral steroids and/or antibiotics; 6. no changes to regular asthma medication during 4 weeks before entry; 7. able to correctly inhale via a Diskus inhaler; 8. able to perform reproducible lung function tests.
Exclusion criteria were as follows: 1. comorbidity likely to interfere with the study; 2.
lower respiratory tract infection during 4 weeks before entry; 3. use of theophyline, sodium cromoglycate, nedocromil sodium or antileukotrienes during the study or antibiotics 4 weeks prior to the study; 4. current smoking, regularly smoking within 6 months before entry or a smoking history of more than 10 pack years; 5. pregnant or lactating females; 6. unable to follow the therapy instructions; 7. participation in another clinical trial within 4 weeks prior to the study. The participating patients were recruited via advertisement and via the outpatient department of Pulmonology at the Academic Medical Center (AMC). The Medical Ethical Committee approved the study and all subjects gave written informed consent.
Study design
A schedule of the study design is shown in Figure 1 . The study had a double-blind, randomized, two-armed parallel design (Figure 1 ). After a 2-week steroid wash-out period, a 4-week run-in period with fluticasone propionate 250 µg twice daily and a baseline bronchial allergen challenge, eligible patients were randomized to receive 1 year of twice daily treatment with either fluticasone propionate (250 µg) or twice daily treatment with fluticasone in a combination inhaler with salmeterol (250/50 µg). Patients were provided with rescue salbutamol 200 µg (GlaxoSmithKline, Zeist, The Netherlands) for relieve of symptoms during the study. All drugs were administered via a dry powder inhaler (Diskus). At the start of the wash-out period a full medical history, physical examination and FEV 1 were performed.
Baseline values were measured at the end of the run-in period. Other visits were scheduled after the wash-out period and during the randomized treatment period after 1, 6, 9 (no PC 20 histamine), 11 (no inflammatory parameters) and 12 months of randomization. In addition, a bronchial allergen challenge was performed one day before randomization and at the end of the randomized treatment period. In order to measure differences in allergeninduced changes between both groups outcomes were determined 24 hours before and 24 hours after bronchial allergen challenges, which were performed at the end of the run-in period (pre-randomization challenge) and at the end of the randomized treatment period (endof-treatment challenge) (Figure 1) . A daily dairy card was completed during two weeks preceding every visit, an additional dairy card was completed after 3 months of randomization. The cards contained peak expiratory flows, rescue-short-acting β 2 -agonist usage and morning and evening symptoms scores (score 0-4 and 0-5 respectively). Before every visit patients abstained from rescue salbutamol (except before the end-wash-out visit) for 8 hours and from the study medication for 12 hours. Before the visit at 11 months of randomization patients abstained from the study medication for 36 hours, to exclude the influence of bronchodilatory effects of salmeterol on the level of PC 20 histamine. Asthma exacerbations were treated either by increasing the dose of fluticasone (defined as a mild exacerbation) or by oral glucocorticosteroids (moderate exacerbation), as judged by the investigator.
Lung function and allergy tests
The FEV 1 was measured at each visit with a dry rolling seal spirometer (Sensor Medics BV, The Netherlands) according to standardized guidelines [2] . Values are expressed as the percentage of the predictive value. Bronchial hyperresponsiveness to histamine (PC 20 histamine) was determined by a 2-minute tidal breathing method [2] . PC 20 histamine was not performed if FEV 1 was ≤ 60 %of the predicted value or if salbutamol could not be abstained during 8 hours before the measurement. Total and specific Immunoglobulin-E directed against house dust mite were determined, as reported previously [3] .
Bronchial allergen challenge A standardized Dermatophagoides pteronyssinus, cat dander or grass pollen extract (containing 50.000 biological units (BU), ALK Abelló, Nieuwegein, The Netherlands) was used for the bronchial allergen challenges. Dilutions of the allergen extract, containing 5000 BU/ml were kept at -20 ºC in aliquots of 0.5 ml. A dilution, containing 200 BU/ml, was made freshly from the stock immediately before use, in phosphate buffered saline, 0.03% human serum albumin, 0.5% phenol (ALK Abelló, Nieuwegein, The Netherlands), of which a 0.5 ml sample was nebulized during the bronchial allergen challenge. A reservoir aerosol delivery system was used according to the method described by Sterk and colleagues [2] with modifications [4] . Briefly, a collapsible reservoir of approximately 30 liter, made of static field dissipative material (RCAS 1206, Richmond Redlands, CA, USA) and filled with dry air, was connected to a nebulizer (Mallinckrodt Diagnostica, Petten, The Netherlands) producing aerosols from a 0.5 ml sample of diluted HDM extract. Previous studies demonstrated a 70% recovery of nebulized allergen. The amount of allergen was not titrated on the decline in FEV 1 during the early asthmatic reaction. For patients convenience all bronchial allergen challenges were preceded 15 minutes before the challenge by the inhalation salbutamol hemisulphate, 500 mg/ml solution, which was nebulized, via a Micro-Mist nebulizer, (Hudson, Ternecula, California, USA) driven by dry-compressed air, at a flow of 5 L/min during 1.5 min. The dose is equivalent to approximately 400 µg salbutamol via a dry powder inhaler, considering the loss of drug by delivering during both inspiration and expiration [5] . The amount of allergen administered to the patients (70 % of 100 biological units, (for Dermatophagoides pteronyssinus equivalent to 42 ng major allergen Der p1) was based on the results of an earlier study which was done in asthma patients with a similar range of severity [6] . However, the patients in that study abstained from anti-inflammatory therapy 6 weeks prior to allergen challenge [6] . The median cumulative dose of allergen that 
Protein assays
Levels of ECP were determined with an ELISA [7] . The detection limit was 15 pg/ml. Assay reagents (Rabbit-anti-human ECP antiserum and anti-ECP antibody-biotin) were kindly donated by dr. A. Zuurbier (CLB Sanquin, Amsterdam, The Netherlands). A series of standard dilutions of ECP was obtained from Pharmacia & Upjohn (Uppsala, Sweden). Major basic protein (MPO) [8] and interleukin (IL)-8 [9] were measured with an ELISA as described earlier. Size selectivity of plasma protein leakage across the respiratory membrane, into the airway lumen was analyzed by measuring the relative coefficient of excretion (RCE s ), which is defined as the ratio of α2-macroglobulin and albumin in valid sputum samples [10, 11] . The levels of albumin were measured by an immunoturbidimetric assay with a Cobas Bio analyzer (Roche Diagnostics, Inc.). Antiserum for albumin was obtained from Dako (code A001, Glostrup, Denmark). As a standard we used N protein standard serum for nephelometry (Behring, Marburg, Germany). The levels of A2M were measured with an ELISA [11] .
Statistical analysis
SAS (SAS Institute Inc., Cary, NC, USA version 8.2) was used for statistical analyses. The study had 80 % power to detect a 50% difference in change from baseline between the groups with a sample size of 54 subjects. Changes over the run-in period were determined using Wilcoxon signed ranks test, or in case of normally distributed data with t-test. Differences within and between the treatment-groups were determined using a mixed model ANOVA, adjusted for differences at baseline (end of run-in). Differences in allergen-induced changes were determined using ANCOVA and adjusted for baseline allergen-induced changes.
Differences between the treatment groups in changes from baseline in PC 20 histamine at the visit at 11 months of randomization were analyzed by multiple linear regression analysis, including baseline PC 20 histamine as co-variable. All p-values are two-tailed and p-levels of less than 0.05 were considered significant.
